JP2018536390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536390A5 JP2018536390A5 JP2018517357A JP2018517357A JP2018536390A5 JP 2018536390 A5 JP2018536390 A5 JP 2018536390A5 JP 2018517357 A JP2018517357 A JP 2018517357A JP 2018517357 A JP2018517357 A JP 2018517357A JP 2018536390 A5 JP2018536390 A5 JP 2018536390A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- eukaryotic cell
- seq
- trc1
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131109A JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2023133416A JP2023175698A (ja) | 2015-10-05 | 2023-08-18 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2025092415A JP2025143265A (ja) | 2015-10-05 | 2025-06-03 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237382P | 2015-10-05 | 2015-10-05 | |
| US62/237,382 | 2015-10-05 | ||
| US201662297445P | 2016-02-19 | 2016-02-19 | |
| US62/297,445 | 2016-02-19 | ||
| PCT/US2016/055472 WO2017062439A1 (en) | 2015-10-05 | 2016-10-05 | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131109A Division JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536390A JP2018536390A (ja) | 2018-12-13 |
| JP2018536390A5 true JP2018536390A5 (https=) | 2019-11-14 |
| JP6929837B2 JP6929837B2 (ja) | 2021-09-15 |
Family
ID=57184827
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517357A Active JP6929837B2 (ja) | 2015-10-05 | 2016-10-05 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2021131109A Pending JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2023133416A Pending JP2023175698A (ja) | 2015-10-05 | 2023-08-18 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2025092415A Pending JP2025143265A (ja) | 2015-10-05 | 2025-06-03 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131109A Pending JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2023133416A Pending JP2023175698A (ja) | 2015-10-05 | 2023-08-18 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2025092415A Pending JP2025143265A (ja) | 2015-10-05 | 2025-06-03 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10799535B2 (https=) |
| EP (3) | EP3359660B1 (https=) |
| JP (4) | JP6929837B2 (https=) |
| AU (4) | AU2016333886B2 (https=) |
| CA (1) | CA3001008A1 (https=) |
| DK (2) | DK3359660T3 (https=) |
| ES (2) | ES2883116T3 (https=) |
| WO (1) | WO2017062439A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3359660B1 (en) * | 2015-10-05 | 2019-12-04 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| JP6816133B2 (ja) * | 2015-10-05 | 2021-01-20 | プレシジョン バイオサイエンシズ，インク． | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| US20190161530A1 (en) * | 2016-04-07 | 2019-05-30 | Bluebird Bio, Inc. | Chimeric antigen receptor t cell compositions |
| EP4628587A3 (en) | 2016-04-15 | 2026-02-25 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| EP3645038B1 (en) | 2017-06-30 | 2026-02-18 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| EP4269560A3 (en) * | 2017-10-03 | 2024-01-17 | Precision Biosciences, Inc. | Modified epidermal growth factor receptor peptides for use in genetically-modified cells |
| JP7101419B2 (ja) * | 2017-10-27 | 2022-07-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 内因性ｔ細胞受容体の標的置換 |
| SG11202004026QA (en) * | 2017-10-30 | 2020-05-28 | Pact Pharma Inc | Primary cell gene editing |
| WO2019089913A1 (en) * | 2017-11-01 | 2019-05-09 | Precision Biosciences, Inc. | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
| IL277722B2 (en) | 2018-04-02 | 2025-12-01 | Pact Pharma Inc | Peptide-mhc compacts |
| US11786554B2 (en) * | 2018-04-12 | 2023-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
| US12467077B2 (en) * | 2018-11-19 | 2025-11-11 | Altius Institute For Biomedical Sciences | Compositions and methods for DNA modification detection |
| EP3921419B1 (en) * | 2019-02-08 | 2026-04-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Sirt2-ablated chimeric t cells |
| IL285534B2 (en) | 2019-02-12 | 2025-04-01 | Pact Pharma Inc | Preparations and methods for identifying antigen-specific T cells |
| WO2020205759A1 (en) * | 2019-03-29 | 2020-10-08 | Pact Pharma, Inc. | Personalized neoantigen-specific adoptive cell therapies |
| KR102691932B1 (ko) | 2019-04-03 | 2024-08-06 | 프리시젼 바이오사이언시스 인코포레이티드 | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 |
| CN114026228A (zh) | 2019-05-07 | 2022-02-08 | 精密生物科学公司 | 用于识别序列的工程化大范围核酸酶的优化 |
| US20220273715A1 (en) | 2019-07-25 | 2022-09-01 | Precision Biosciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
| CA3148179A1 (en) | 2019-08-20 | 2021-02-25 | Bruce J. Mccreedy Jr. | Lymphodepletion dosing regimens for cellular immunotherapies |
| WO2021044373A2 (en) * | 2019-09-06 | 2021-03-11 | Avectas Limited | Engineering of immune cells for ex vivo cell therapy applications |
| US20220411479A1 (en) | 2019-10-30 | 2022-12-29 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| CA3159557A1 (en) * | 2019-11-05 | 2021-05-14 | Lonza Walkersville, Inc. | Allogeneic t-cells and methods for production thereof |
| WO2021113543A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells |
| US20230183664A1 (en) | 2020-05-11 | 2023-06-15 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| EP4192875A1 (en) | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| US20250127811A1 (en) | 2021-01-28 | 2025-04-24 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| WO2022226305A1 (en) * | 2021-04-22 | 2022-10-27 | Precision Biosciences, Inc. | Engineered meganucleases that target human mitochondrial genomes |
| WO2023064872A1 (en) | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| US20250064986A1 (en) | 2022-01-07 | 2025-02-27 | Precision Biosciences, Inc. | Optimized polynucleotides for protein expression |
| WO2024148167A1 (en) | 2023-01-05 | 2024-07-11 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene |
| WO2024236547A1 (en) | 2023-05-18 | 2024-11-21 | Inceptor Bio, Llc | Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof |
| WO2025046513A1 (en) | 2023-08-29 | 2025-03-06 | Inceptor Bio, Llc | Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof |
| WO2026047626A1 (en) | 2024-08-30 | 2026-03-05 | Inceptor Bio, Llc | Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy |
| WO2026083328A1 (en) | 2024-10-18 | 2026-04-23 | Precision Biosciences, Inc. | Base editing nucleotide sequences using homology directed repair |
| WO2026083329A1 (en) | 2024-10-18 | 2026-04-23 | Precision Biosciences, Inc. | Methods of nuclease-initiated homology directed repair and replacement and compositions and uses thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| US20100151556A1 (en) | 2002-03-15 | 2010-06-17 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| ES2582091T3 (es) * | 2005-10-18 | 2016-09-09 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| WO2010015899A2 (en) | 2008-08-04 | 2010-02-11 | Cellectis | Novel method to generate meganucleases with altered characteristics |
| EP2215223B1 (en) * | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| AU2011281062B2 (en) * | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| EP2714936B1 (en) | 2011-06-01 | 2018-12-12 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| BR112014029417B1 (pt) | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| KR20140019635A (ko) | 2012-08-06 | 2014-02-17 | 엘지이노텍 주식회사 | 발광 소자 및 발광 소자 패키지 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
| WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| ES2716867T3 (es) | 2013-05-31 | 2019-06-17 | Cellectis Sa | Endonucleasa de asentamiento LAGLIDADG que escinde el gen de receptor de células T alfa y usos de la misma |
| CA2913871C (en) | 2013-05-31 | 2021-07-13 | Cellectis | A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof |
| EP3441468B1 (en) | 2013-10-17 | 2021-05-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| WO2015121454A1 (en) | 2014-02-14 | 2015-08-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| JP6681837B2 (ja) | 2014-03-11 | 2020-04-15 | セレクティスＣｅｌｌｅｃｔｉｓ | 同種移植に適合するｔ細胞を作製するための方法 |
| EP4659765A3 (en) * | 2014-03-12 | 2026-02-18 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
| US10494422B2 (en) | 2014-04-29 | 2019-12-03 | Seattle Children's Hospital | CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies |
| HRP20200529T1 (hr) | 2014-06-06 | 2020-09-04 | Regeneron Pharmaceuticals, Inc. | Postupci i pripravci za modificiranje ciljnog lokusa |
| JP2017529841A (ja) | 2014-09-19 | 2017-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | キメラ抗原受容体 |
| US20170335331A1 (en) | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| AU2016243583B2 (en) | 2015-03-27 | 2022-03-10 | President And Fellows Of Harvard College | Modified T cells and methods of making and using the same |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| AU2016291778B2 (en) | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| JP6816133B2 (ja) | 2015-10-05 | 2021-01-20 | プレシジョン バイオサイエンシズ，インク． | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| EP3359660B1 (en) | 2015-10-05 | 2019-12-04 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| WO2017070429A1 (en) | 2015-10-22 | 2017-04-27 | Regents Of The University Of Minnesota | Methods involving editing polynucleotides that encode t cell receptor |
| CA3009637A1 (en) * | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| JP2019509738A (ja) | 2016-03-11 | 2019-04-11 | ブルーバード バイオ， インコーポレイテッド | ゲノム編集された免疫エフェクター細胞 |
| EP4628587A3 (en) | 2016-04-15 | 2026-02-25 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| EP3645038B1 (en) | 2017-06-30 | 2026-02-18 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| US11786554B2 (en) | 2018-04-12 | 2023-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
-
2016
- 2016-10-05 EP EP16785045.2A patent/EP3359660B1/en active Active
- 2016-10-05 DK DK16785045.2T patent/DK3359660T3/da active
- 2016-10-05 WO PCT/US2016/055472 patent/WO2017062439A1/en not_active Ceased
- 2016-10-05 US US15/766,290 patent/US10799535B2/en active Active
- 2016-10-05 CA CA3001008A patent/CA3001008A1/en active Pending
- 2016-10-05 EP EP19212310.7A patent/EP3680329B1/en active Active
- 2016-10-05 EP EP21177206.6A patent/EP3940070A1/en active Pending
- 2016-10-05 ES ES19212310T patent/ES2883116T3/es active Active
- 2016-10-05 JP JP2018517357A patent/JP6929837B2/ja active Active
- 2016-10-05 AU AU2016333886A patent/AU2016333886B2/en active Active
- 2016-10-05 ES ES16785045T patent/ES2768984T3/es active Active
- 2016-10-05 DK DK19212310.7T patent/DK3680329T3/da active
-
2020
- 2020-09-09 US US17/016,056 patent/US11266693B2/en active Active
- 2020-12-15 AU AU2020289750A patent/AU2020289750B2/en active Active
-
2021
- 2021-08-11 JP JP2021131109A patent/JP2022000019A/ja active Pending
-
2022
- 2022-01-31 US US17/589,594 patent/US20220152112A1/en not_active Abandoned
-
2023
- 2023-04-03 AU AU2023202022A patent/AU2023202022A1/en not_active Abandoned
- 2023-08-18 JP JP2023133416A patent/JP2023175698A/ja active Pending
-
2024
- 2024-08-02 US US18/793,199 patent/US20240382526A1/en active Pending
-
2025
- 2025-06-03 JP JP2025092415A patent/JP2025143265A/ja active Pending
- 2025-11-24 AU AU2025271174A patent/AU2025271174A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536390A5 (https=) | ||
| JP2018535663A5 (https=) | ||
| US11268065B2 (en) | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene | |
| US20220152112A1 (en) | Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene | |
| CA3151690A1 (en) | Genetically-edited immune cells and methods of therapy | |
| KR20220016475A (ko) | 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법 | |
| JP2021520800A5 (https=) | ||
| CN110139675A (zh) | 用具有工程化稳定的内源性foxp3基因表达的cd4 t细胞治疗自身免疫疾病的方法 | |
| KR20230157387A (ko) | Cas 효소를 이용한 다중 편집 | |
| HK40087901A (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK40043947A (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK40043947B (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK1259673A1 (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK1259673B (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |